MedTrace Logo

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

NCT05008536 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2021-11-23

No results posted yet for this study

Summary

The purpose of this study is to infuse BCMA CAR-NK cells（Umbilical \& Cord Blood (CB) Derived CAR-Engineered NK Cells） to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.

Conditions

  • Multiple Myeloma, Refractory

Interventions

BIOLOGICAL

Anti-BCMA CAR-NK Cells

1-3×10\^6 /KG, 3-6×10\^6 /KG, 0.6-1.2×10\^7/KG Treatment follows a lymphodepletion

DRUG

Fludarabine

recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

DRUG

Cytoxan

recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

Sponsors & Collaborators

  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Xinqiao Hospital of Chongqing

    lead OTHER

Principal Investigators

  • xi zhang, PhD/MD · Department of Hematology, Xinqiao Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-09-01
Completion
2023-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05008536 on ClinicalTrials.gov